StemCells Partners With R Biomedical, Cardinal Health Faces Generics: Healthcare Business Recap

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

StemCells (NASDAQ:STEM) is collaborating with the Edinburgh-based R Biomedical in the development and commercialization of a range of cell lines and reagents for use in stem cell-based research for regenerative medicine applications. On Tuesday, the first product under the partnership was introduced under StemCells’ SC Proven brand, which is an “ultra-primary” human fibroblast cell line from which researchers can fabricate iPS cell lines.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Cardinal Health (NYSE:CAH) faces rising sales of generic drugs that are less expensive, but are able to bring higher margins. The firm’s fiscal first quarter net profit rose by 15 percent to $271 million, as pharmaceutical revenue slipped 4 percent to $23.5 billion. However, profit jumped by 10 percent and medical business revenue rose by 1 percent to $2.39 billion. Cardinal anticipates its fiscal year earnings per share to be between $3.35 and $3.50, versus consensus of $3.43.

Patients being treated with Eli Lilly and Company’s (NYSE:LLY) solanezumab in two Phase III trials had their blood levels of beta amyloid, a protein linked with Alzheimer’s, increased, implying that the protein was removed from the brain as intended. It has been previously reported that Solanezumab appears to have the capacity to slow Alzheimer’s progression in patients exhibiting mild symptoms, so the latest finding suggests validity to the concepts that amyloid is a cause.

Don’t Miss: Oops! Johnson & Johnson Forced to Recall This Dangerous Product.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business